Charles Zhou
Stock Analyst at UBS
(0.48)
# 3,043
Out of 4,415 analysts
8
Total ratings
50%
Success rate
-17.79%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Upgrades: Buy | $67 | $64.10 | +4.52% | 2 | Jan 5, 2024 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $8.76 | +82.65% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $6.93 | +116.45% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $15.55 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | n/a | $1.86 | - | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | n/a | $3.30 | - | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.40 | - | 1 | Jan 22, 2020 |
Futu Holdings
Jan 5, 2024
Upgrades: Buy
Price Target: $67
Current: $64.10
Upside: +4.52%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $8.76
Upside: +82.65%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $6.93
Upside: +116.45%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $15.55
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: n/a
Current: $1.86
Upside: -
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: n/a
Current: $3.30
Upside: -
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.40
Upside: -